AbbVie Inc. $ABBV Shares Sold by Beaumont Financial Advisors LLC

Beaumont Financial Advisors LLC decreased its position in AbbVie Inc. (NYSE:ABBV) by 25.5% during the 4th quarter, Holdings Channel reports. The fund owned 8,261 shares of the company’s stock after selling 2,824 shares during the quarter. Beaumont Financial Advisors LLC’s holdings in AbbVie were worth $1,888,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Chelsea Counsel Co. purchased a new stake in AbbVie in the 3rd quarter valued at approximately $26,000. Westend Capital Management LLC acquired a new position in AbbVie during the 4th quarter worth approximately $29,000. Texas Capital Bancshares Inc TX purchased a new position in shares of AbbVie during the 3rd quarter worth approximately $31,000. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie in the 2nd quarter valued at approximately $26,000. Finally, Caitlin John LLC acquired a new stake in shares of AbbVie in the 3rd quarter valued at approximately $33,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Price Performance

NYSE ABBV opened at $208.79 on Friday. The business has a 50 day moving average price of $221.79 and a 200 day moving average price of $224.48. The company has a market capitalization of $369.17 billion, a P/E ratio of 88.47, a PEG ratio of 0.75 and a beta of 0.38. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the previous year, the business earned $2.16 earnings per share. AbbVie’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

Analyst Ratings Changes

ABBV has been the topic of a number of recent analyst reports. Citigroup dropped their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Finally, Morgan Stanley raised their price objective on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.